Agilent Technologies (NYSE:A) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Key Points

• Wells Fargo & Company has raised Agilent Technologies' price objective from $135.00 to $140.00, indicating a potential upside of 14.15% from its current price.
• The consensus rating for Agilent Technologies is "Moderate Buy" with an average price target of $139.08, supported by multiple analysts providing "Buy" ratings.
• Agilent Technologies reported a 10.1% year-over-year increase in revenue for the most recent quarter, meeting earnings per share estimates while also guiding for future performance.

Agilent Technologies (NYSE:A - Get Free Report) had its price objective raised by equities researchers at Wells Fargo & Company from $135.00 to $140.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an "overweight" rating on the medical research company's stock. Wells Fargo & Company's price objective would suggest a potential upside of 14.15% from the stock's current price.

A has been the subject of a number of other reports. Barclays upped their target price on Agilent Technologies from $115.00 to $125.00 and gave the company an "equal weight" rating in a research report on Tuesday, June 24th. Evercore ISI reduced their price objective on shares of Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating on the stock in a research note on Thursday. JPMorgan Chase & Co. decreased their target price on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating on the stock in a report on Thursday, May 29th. TD Cowen boosted their target price on shares of Agilent Technologies to $150.00 and gave the company a "buy" rating in a research report on Thursday, May 29th. Finally, Leerink Partners increased their price target on shares of Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research report on Friday, May 30th. Six research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, Agilent Technologies has a consensus rating of "Moderate Buy" and an average price target of $139.08.

Agilent Technologies Stock Performance

Shares of NYSE A traded up $3.96 during midday trading on Thursday, hitting $122.65. 705,569 shares of the company's stock were exchanged, compared to its average volume of 1,932,636. The company has a quick ratio of 1.60, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $34.84 billion, a PE ratio of 30.25, a price-to-earnings-growth ratio of 3.59 and a beta of 1.22. Agilent Technologies has a 12 month low of $96.43 and a 12 month high of $153.84. The company's 50 day moving average price is $117.99 and its 200 day moving average price is $116.89.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting analysts' consensus estimates of $1.37. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. Agilent Technologies's quarterly revenue was up 10.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, analysts predict that Agilent Technologies will post 5.58 earnings per share for the current fiscal year.

Insider Buying and Selling at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the company's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the sale, the chief executive officer owned 37,448 shares in the company, valued at approximately $4,397,893.12. The trade was a 3.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Hedge Funds Weigh In On Agilent Technologies

Large investors have recently modified their holdings of the company. Norges Bank purchased a new position in shares of Agilent Technologies in the second quarter worth about $395,088,000. AQR Capital Management LLC boosted its holdings in Agilent Technologies by 424.1% in the 2nd quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company's stock worth $240,956,000 after buying an additional 1,652,244 shares during the period. Ameriprise Financial Inc. grew its stake in Agilent Technologies by 132.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company's stock valued at $277,807,000 after buying an additional 1,340,161 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Agilent Technologies by 10.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 13,227,387 shares of the medical research company's stock valued at $1,560,964,000 after acquiring an additional 1,273,994 shares during the period. Finally, Generation Investment Management LLP raised its holdings in Agilent Technologies by 19.8% during the 1st quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company's stock valued at $582,976,000 after acquiring an additional 824,243 shares during the period.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.